A citation-based method for searching scientific literature

Bruce E Sands, Jingjing Chen, Brian G Feagan, Mark Penney, William A Rees, Silvio Danese, Peter D R Higgins, Paul Newbold, Raffaella Faggioni, Kaushik Patra, Jing Li, Paul Klekotka, Chris Morehouse, Erik Pulkstenis, Jörn Drappa, René van der Merwe, Robert A Gasser. Gastroenterology 2017
Times Cited: 155







List of co-cited articles
1241 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study.
Brian G Feagan, William J Sandborn, Geert D'Haens, Julián Panés, Arthur Kaser, Marc Ferrante, Edouard Louis, Denis Franchimont, Olivier Dewit, Ursula Seidler,[...]. Lancet 2017
254
64

Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.
Brian G Feagan, William J Sandborn, Christopher Gasink, Douglas Jacobstein, Yinghua Lang, Joshua R Friedman, Marion A Blank, Jewel Johanns, Long-Long Gao, Ye Miao,[...]. N Engl J Med 2016
838
56

Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis.
Bruce E Sands, William J Sandborn, Remo Panaccione, Christopher D O'Brien, Hongyan Zhang, Jewel Johanns, Omoniyi J Adedokun, Katherine Li, Laurent Peyrin-Biroulet, Gert Van Assche,[...]. N Engl J Med 2019
352
31

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.
Wolfgang Hueber, Bruce E Sands, Steve Lewitzky, Marc Vandemeulebroecke, Walter Reinisch, Peter D R Higgins, Jan Wehkamp, Brian G Feagan, Michael D Yao, Marek Karczewski,[...]. Gut 2012
953
30

Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study.
Brian G Feagan, Julián Panés, Marc Ferrante, Arthur Kaser, Geert R D'Haens, William J Sandborn, Edouard Louis, Markus F Neurath, Denis Franchimont, Olivier Dewit,[...]. Lancet Gastroenterol Hepatol 2018
88
34

A genome-wide association study identifies IL23R as an inflammatory bowel disease gene.
Richard H Duerr, Kent D Taylor, Steven R Brant, John D Rioux, Mark S Silverberg, Mark J Daly, A Hillary Steinhart, Clara Abraham, Miguel Regueiro, Anne Griffiths,[...]. Science 2006
26

Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial.
Séverine Vermeire, Stefan Schreiber, Robert Petryka, Tanja Kuehbacher, Xavier Hebuterne, Xavier Roblin, Maria Klopocka, Adrian Goldis, Maria Wisniewska-Jarosinska, Andrey Baranovsky,[...]. Lancet 2017
243
25

Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis.
William J Sandborn, Marc Ferrante, Bal R Bhandari, Elina Berliba, Brian G Feagan, Toshifumi Hibi, Jay L Tuttle, Paul Klekotka, Stuart Friedrich, Michael Durante,[...]. Gastroenterology 2020
60
41

Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis.
William J Sandborn, Chinyu Su, Bruce E Sands, Geert R D'Haens, Séverine Vermeire, Stefan Schreiber, Silvio Danese, Brian G Feagan, Walter Reinisch, Wojciech Niezychowski,[...]. N Engl J Med 2017
671
24

Vedolizumab as induction and maintenance therapy for Crohn's disease.
William J Sandborn, Brian G Feagan, Paul Rutgeerts, Stephen Hanauer, Jean-Frédéric Colombel, Bruce E Sands, Milan Lukas, Richard N Fedorak, Scott Lee, Brian Bressler,[...]. N Engl J Med 2013
24

Vedolizumab as induction and maintenance therapy for ulcerative colitis.
Brian G Feagan, Paul Rutgeerts, Bruce E Sands, Stephen Hanauer, Jean-Frédéric Colombel, William J Sandborn, Gert Van Assche, Jeffrey Axler, Hyo-Jong Kim, Silvio Danese,[...]. N Engl J Med 2013
23

IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6.
David Yen, Jeanne Cheung, Heleen Scheerens, Frédérique Poulet, Terrill McClanahan, Brent McKenzie, Melanie A Kleinschek, Alex Owyang, Jeanine Mattson, Wendy Blumenschein,[...]. J Clin Invest 2006
23

Ustekinumab induction and maintenance therapy in refractory Crohn's disease.
William J Sandborn, Christopher Gasink, Long-Long Gao, Marion A Blank, Jewel Johanns, Cynthia Guzzo, Bruce E Sands, Stephen B Hanauer, Stephan Targan, Paul Rutgeerts,[...]. N Engl J Med 2012
735
22

IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease.
Alessandra Geremia, Carolina V Arancibia-Cárcamo, Myles P P Fleming, Nigel Rust, Baljit Singh, Neil J Mortensen, Simon P L Travis, Fiona Powrie. J Exp Med 2011
462
20

Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial.
Séverine Vermeire, Sharon O'Byrne, Mary Keir, Marna Williams, Timothy T Lu, John C Mansfield, Christopher A Lamb, Brian G Feagan, Julian Panes, Azucena Salas,[...]. Lancet 2014
306
18

Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial.
Séverine Vermeire, William J Sandborn, Silvio Danese, Xavier Hébuterne, Bruce A Salzberg, Maria Klopocka, Dino Tarabar, Tomas Vanasek, Miloš Greguš, Paul A Hellstern,[...]. Lancet 2017
107
17

Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12.
B Oppmann, R Lesley, B Blom, J C Timans, Y Xu, B Hunte, F Vega, N Yu, J Wang, K Singh,[...]. Immunity 2000
17

Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease.
Luke Jostins, Stephan Ripke, Rinse K Weersma, Richard H Duerr, Dermot P McGovern, Ken Y Hui, James C Lee, L Philip Schumm, Yashoda Sharma, Carl A Anderson,[...]. Nature 2012
17

Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis.
Kim A Papp, Andrew Blauvelt, Michael Bukhalo, Melinda Gooderham, James G Krueger, Jean-Philippe Lacour, Alan Menter, Sandra Philipp, Howard Sofen, Stephen Tyring,[...]. N Engl J Med 2017
285
17

Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease.
Nathaniel R West, Ahmed N Hegazy, Benjamin M J Owens, Samuel J Bullers, Bryan Linggi, Sofia Buonocore, Margherita Coccia, Dieter Görtz, Sébastien This, Krista Stockenhuber,[...]. Nat Med 2017
335
17

IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting.
Alexander R Moschen, Herbert Tilg, Tim Raine. Nat Rev Gastroenterol Hepatol 2019
160
17

A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R.
Christi Parham, Madaline Chirica, Jacqueline Timans, Elena Vaisberg, Marilyn Travis, Jeanne Cheung, Stefan Pflanz, Rebecca Zhang, Komal P Singh, Felix Vega,[...]. J Immunol 2002
961
16

Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology.
Holm H Uhlig, Brent S McKenzie, Sophie Hue, Claire Thompson, Barbara Joyce-Shaikh, Renata Stepankova, Nicolas Robinson, Sofia Buonocore, Helena Tlaskalova-Hogenova, Daniel J Cua,[...]. Immunity 2006
499
16

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn's Disease.
Stephan R Targan, Brian Feagan, Severine Vermeire, Remo Panaccione, Gil Y Melmed, Carol Landers, Dalin Li, Chris Russell, Richard Newmark, Nan Zhang,[...]. Am J Gastroenterol 2016
204
16

Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
Kenneth B Gordon, Bruce Strober, Mark Lebwohl, Matthias Augustin, Andrew Blauvelt, Yves Poulin, Kim A Papp, Howard Sofen, Lluís Puig, Peter Foley,[...]. Lancet 2018
258
16

Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology.
Sofia Buonocore, Philip P Ahern, Holm H Uhlig, Ivaylo I Ivanov, Dan R Littman, Kevin J Maloy, Fiona Powrie. Nature 2010
813
15

Differential Roles for Interleukin-23 and Interleukin-17 in Intestinal Immunoregulation.
Joseph R Maxwell, Yu Zhang, William A Brown, Carole L Smith, Fergus R Byrne, Mike Fiorino, Erin Stevens, Jeannette Bigler, John A Davis, James B Rottman,[...]. Immunity 2015
204
15

Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis.
William J Sandborn, Brian G Feagan, Douglas C Wolf, Geert D'Haens, Severine Vermeire, Stephen B Hanauer, Subrata Ghosh, Heather Smith, Matthew Cravets, Paul A Frohna,[...]. N Engl J Med 2016
262
14

Infliximab for induction and maintenance therapy for ulcerative colitis.
Paul Rutgeerts, William J Sandborn, Brian G Feagan, Walter Reinisch, Allan Olson, Jewel Johanns, Suzanne Travers, Daniel Rachmilewitz, Stephen B Hanauer, Gary R Lichtenstein,[...]. N Engl J Med 2005
14

Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn's disease.
Heike Schmitt, Ulrike Billmeier, Walburga Dieterich, Timo Rath, Sophia Sonnewald, Stephen Reid, Simon Hirschmann, Kai Hildner, Maximilian J Waldner, Jonas Mudter,[...]. Gut 2019
79
17

Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn's disease: report of the OPERA study.
William J Sandborn, Scott D Lee, Dino Tarabar, Edouard Louis, Maria Klopocka, Jochen Klaus, Walter Reinisch, Xavier Hébuterne, Dong-Il Park, Stefan Schreiber,[...]. Gut 2018
55
25

Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis.
William J Sandborn, Laurent Peyrin-Biroulet, Jinkun Zhang, Michael Chiorean, Séverine Vermeire, Scott D Lee, Tanja Kühbacher, Bruce Yacyshyn, Christopher H Cabell, Snehal U Naik,[...]. Gastroenterology 2020
64
21

Inflammatory bowel disease.
Clara Abraham, Judy H Cho. N Engl J Med 2009
13

Anti-interleukin-12 antibody for active Crohn's disease.
Peter J Mannon, Ivan J Fuss, Lloyd Mayer, Charles O Elson, William J Sandborn, Daniel Present, Ben Dolin, Nancy Goodman, Catherine Groden, Ronald L Hornung,[...]. N Engl J Med 2004
628
13

A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease.
William J Sandborn, Brian G Feagan, Richard N Fedorak, Ellen Scherl, Mark R Fleisher, Seymour Katz, Jewel Johanns, Marion Blank, Paul Rutgeerts. Gastroenterology 2008
553
13

The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing.
Sarah L Gaffen, Renu Jain, Abhishek V Garg, Daniel J Cua. Nat Rev Immunol 2014
913
13

Briakinumab for treatment of Crohn's disease: results of a randomized trial.
Remo Panaccione, William J Sandborn, Glenn L Gordon, Scott D Lee, Alan Safdi, Shahriar Sedghi, Brian G Feagan, Stephen Hanauer, Walter Reinisch, John F Valentine,[...]. Inflamm Bowel Dis 2015
59
22

Interleukin-23 drives intestinal inflammation through direct activity on T cells.
Philip P Ahern, Chris Schiering, Sofia Buonocore, Mandy J McGeachy, Dan J Cua, Kevin J Maloy, Fiona Powrie. Immunity 2010
360
12

Secukinumab in plaque psoriasis--results of two phase 3 trials.
Richard G Langley, Boni E Elewski, Mark Lebwohl, Kristian Reich, Christopher E M Griffiths, Kim Papp, Lluís Puig, Hidemi Nakagawa, Lynda Spelman, Bárður Sigurgeirsson,[...]. N Engl J Med 2014
12

IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases.
Michele W L Teng, Edward P Bowman, Joshua J McElwee, Mark J Smyth, Jean-Laurent Casanova, Andrea M Cooper, Daniel J Cua. Nat Med 2015
451
12

Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials.
Julian Panés, William J Sandborn, Stefan Schreiber, Bruce E Sands, Séverine Vermeire, Geert D'Haens, Remo Panaccione, Peter D R Higgins, Jean-Frederic Colombel, Brian G Feagan,[...]. Gut 2017
193
12

Prediction of complicated disease course for children newly diagnosed with Crohn's disease: a multicentre inception cohort study.
Subra Kugathasan, Lee A Denson, Thomas D Walters, Mi-Ok Kim, Urko M Marigorta, Melanie Schirmer, Kajari Mondal, Chunyan Liu, Anne Griffiths, Joshua D Noe,[...]. Lancet 2017
312
12

Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease.
William J Sandborn, Brian G Feagan, Edward V Loftus, Laurent Peyrin-Biroulet, Gert Van Assche, Geert D'Haens, Stefan Schreiber, Jean-Frederic Colombel, James D Lewis, Subrata Ghosh,[...]. Gastroenterology 2020
73
16

Unique CD14 intestinal macrophages contribute to the pathogenesis of Crohn disease via IL-23/IFN-gamma axis.
Nobuhiko Kamada, Tadakazu Hisamatsu, Susumu Okamoto, Hiroshi Chinen, Taku Kobayashi, Toshiro Sato, Atsushi Sakuraba, Mina T Kitazume, Akira Sugita, Kazutaka Koganei,[...]. J Clin Invest 2008
440
11

IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn's disease.
T Kobayashi, S Okamoto, T Hisamatsu, N Kamada, H Chinen, R Saito, M T Kitazume, A Nakazawa, A Sugita, K Koganei,[...]. Gut 2008
387
11

Interleukin-23-Independent IL-17 Production Regulates Intestinal Epithelial Permeability.
Jacob S Lee, Cristina M Tato, Barbara Joyce-Shaikh, Muhammet F Gulen, Corinne Cayatte, Yi Chen, Wendy M Blumenschein, Michael Judo, Gulesi Ayanoglu, Terrill K McClanahan,[...]. Immunity 2015
395
11

Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis.
William J Sandborn, Subrata Ghosh, Julian Panes, Stefan Schreiber, Geert D'Haens, Satoshi Tanida, Jesse Siffledeen, Jeffrey Enejosa, Wen Zhou, Ahmed A Othman,[...]. Gastroenterology 2020
67
16

Cytokines in inflammatory bowel disease.
Markus F Neurath. Nat Rev Immunol 2014
10

The increased expression of IL-23 in inflammatory bowel disease promotes intraepithelial and lamina propria lymphocyte inflammatory responses and cytotoxicity.
Zhanju Liu, Praveen K Yadav, Xiaorong Xu, Jingling Su, Chi Chen, Maochun Tang, Hui Lin, Jifeng Yu, Jiaming Qian, Ping-Chang Yang,[...]. J Leukoc Biol 2011
95
10

Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain.
Daniel J Cua, Jonathan Sherlock, Yi Chen, Craig A Murphy, Barbara Joyce, Brian Seymour, Linda Lucian, Wayne To, Sylvia Kwan, Tatyana Churakova,[...]. Nature 2003
10


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.